Quick Answer
SAB Biotherapeutics, Inc. reported Total Revenue of $0.00 for fiscal year 2025.
SAB Biotherapeutics, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $0.00 | -100.0% |
| 2024 | $1.32M | -40.9% |
| 2023 | $2.24M | -90.6% |
| 2022 | $23.90M | -60.7% |
| 2021 | $60.88M | +10.2% |
| 2020 | $55.24M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| June 30, 2024 | $263.1K | +207.7% | -72.1% |
| March 31, 2024 | $944.6K | +62.5% | -25.5% |
| September 30, 2023 | $1.27M | -64.7% | +1382.0% |
| June 30, 2023 | $85.5K | -98.7% | -85.3% |
| March 31, 2023 | $581.1K | -95.1% | -83.8% |
| September 30, 2022 | $3.59M | -75.5% | -43.5% |
| June 30, 2022 | $6.35M | -65.1% | -46.2% |
| March 31, 2022 | $11.80M | -30.3% | -19.6% |
- SAB Biotherapeutics, Inc. showed a decrease of -100.0% in Total Revenue compared to the prior fiscal year.
- Over the 2020–2025 period, SAB Biotherapeutics, Inc.’s total revenue has declined by 100.0% (from $55.24 million to $0.00).
- The most recent figure is from SAB Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: